ESMO 2018 Zoledronic acid improves diseasefree survival in premenopausal HR early breast cancer

ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer

04:08 EDT 21 Oct 2018 | ecancermedicalscience

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR )...

More From BioPortfolio on "ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer"